Jefferson University Hospitals

Physician Profile

Manish Sharma, MD

Jefferson University Physician

Academic Title: Assistant Professor

Specialties
Medical Oncology - Bone Marrow Transplant (Not Accepting New Patients)
Medical Oncology - Hematologic Malignancies (Not Accepting New Patients)
Medical Oncology (Not Accepting New Patients)

Office Locations

Philadelphia
925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Board Certifications

  • Medical Oncology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Education

  • Ross University School of Medicine, Medical School

Internship

  • West Virginia University School of Medicine

Residency

  • West Virginia University School of Medicine

Fellowship

  • West Virginia University School of Medicine
  • MD Anderson Cancer Center, Houston, TX

Recent Publications

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)

Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer

Genotype-guided dosing study of FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer

PharmGKB summary: Pazopanib pathway, pharmacokinetics

Taking a Measured Approach to Toxicity Data in Phase i Oncology Clinical Trials

Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

Reverse warburg effect in a patient with aggressive B-cell lymphoma: Is lactic acidosis a paraneoplastic syndrome?

Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients

Estimation of renal cell carcinoma treatment effects from disease progression modeling

Models of excellence: Improving oncology drug development

Why RECIST works and why it should stay--reply to counterpoint.

Why RECIST works and why it should stay - Counterpoint

RECIST: No longer the sharpest tool in the oncology clinical trials toolbox - Point/Counterpoint

Dasatinib in previously treated metastatic colorectal cancer: A phase II trial of the University of Chicago Phase II Consortium

Resampling phase III data to assess phase II Trial designs and endpoints

Role of randomized phase III trials in an era of effective targeted therapies

Randomized phase II Trials: A long-term investment with promising returns